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Abstract 
A ferrochelatase (FC) mRNA lacking exon 4 was detected in a patient with erythropoietic protoporphyria (EPP). The mutation 
responsible for the exon skipping was a novel one: a G ~ C transition at the - 1 position of the exon 4 donor site (nucleotide 463). The 
efficiency of missplicing was not 100%. The same mutation could alternatively result in exon 4 skipping or act as a missense mutation 
(G463 --, C, predicting an Ala155 ~ Pro substitution), that inactivates the FC activity almost completely. Both parents were negative for 
the mutation and DNA fingerprinting indicated that both of them are the biological parents with 99.58% certainty. This is the first report 
of a de novo mutation in EPP. 
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1. Introduction 
Ferrochelatase, the last enzyme of heme biosynthesis, 
catalyzes the insertion of ferrous ions into protoporphyrin 
IX. Its deficiency is associated with EPP, a condition 
characterized by accumulation of excess protoporphyrin, 
cutaneous photosensitivity and occasional liver failure. 
The molecular defects underlying EPP have been found 
to be very heterogenous. We have systematically screened 
19 EPP families for FC mRNA with exon skipping and 
found 7 of them to be positive. In 6 families the responsi- 
ble mutations have been previously identified [1]. The 
mutation in the 7th family is described in this paper. The 
mutation, which is associated with exon 4 skipping, was 
found to occur de novo and to have dual effects: it can 
either cause exon 4 skipping or act as a missense mutation 
resulting in profoundly decreased FC activity. 
2. Methods 
Amplification of exon 4 plus its flanking region, and 
sequencing of the amplified fragments were carried out as 
previously described [1]. 
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Evaluation of the mutant FC was accomplished using an 
established expression system [2]. pHDTF20, designed for 
producing high levels of mature length human FC (a 
generous gift of Dr. H.A. Dailey), was used as a positive 
control for all our expression experiments. Construction of 
the mutant-containing expression vector pHDG463 ~ C is 
shown in Fig. 1. The FC cDNA clone bearing the G463 --* 
C transversion was isolated and sequenced to assure that 
no additional mutations were present. The plasmid was 
then subjected to BamHI/PstI digestion to release a FC 
cDNA fragment of 849 bp encompassing the G463 ~ C 
transversion. This 849 bp fragment hen replaced its coun- 
terpart in pHDTF20. A negative control vector (pHDnoE7) 
was similarly constructed using a FC cDNA clone with 
exon 7 skipping. Exon 7 is 99 bp long and therefore the 
BamHI/Pstl digestion released a 750 bp fragment instead 
of an 849 bp fragment. An additional control vector 
(pHDG913 --* T) containing a G913 --* T transversion 
(predicting a Va1305 ~ Phe substitution) [1] was also con- 
structed and included in the expression experiments. 
These FC expression vectors (pHDTF20, pHDG463 
C, pHDnoE7 and pHDG913 ~ T) were expressed in E. 
coli JM109 ceils. Recombinant mature length FC was 
purified according to the published procedure [2]. Briefly, 
an overnight bacterial culture was collected by centrifuga- 
tion and cells were disrupted by homogenization. The 
membrane fraction was isolated by ultracentrifugation a d 
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solubilized by sonication. The solubilized FC was further 
purified by ammonium sulfate precipitation. The resus- 
pended pellet was thus quite enriched in FC, as shown by 
its characteristic amber-color. The final step of the purifi- 
cation was protein chromatography using a Pharmacia Hi 
Trap Blue column. The FC was then eluted and examined 
on the SDS PAGE. The FC activity was determined by 
measuring zinc-chelating activity [3]. 
Blood samples were obtained with informed consent 
according to the ethical standard of the 1964 Declaration 
of Helsinki and with the approval of the Institutional 
Review Boards of both New York Medical College and 
Columbia University. 
3.  Resu l t s  
The patient is a 10-yr-old Caucasian female with mod- 
erately severe cutaneous photosensitivity, but no clinical or 
laboratory evidence of abnormal iver function. Her mean 
erythrocyte protoporphyrin levels over the last 3 yr (6 
measurements in Dr. M. Poh-Fitzpatrick's laboratory) have 
been 1692_+ 408 I~g/dl (normal 42.9 _+ 15.4). Her fer- 
rochelatase activity determined in leukocytes was 32% of 
normal. There is no family history of photosensitivity. Her 
mother's erythrocyte protoporphyrin level was 40 bg /d l :  
her ferrochelatase activity was in the normal range. Her 
father's erythrocyte protoporphyrin level was 60 ~g/d l ;  
his ferrochelatase l vel was also in the normal range. 
Exon 4 skipping was first indicated by hybridization of 
Fig. 1. Construction of FC expression vectors, pHDTF20 = expression 
vector designed by H. Dailey to produce mature length human FC. 
pUCG463--9 C (or pUCG913 ~ T)= pUC clone containing FC cDNA 
with G463 --* C (or G913 ~ T) substitution; pUCnoE7 = pUC clone con- 
taining FC cDNA with exon 7 skipping. From these pUC plasmids, an FC 
cDNA fragment bearing G463 ~ C (or G913 -~ T) substitution a d an FC 
cDNA fragment with exon 7 skipping were respectively released by 
BamHI/PstI digestions. These were next ligated to pHDTF20 linearized 
by the same two restriction enzymes. The symbols used in the figure 
represent: thick line, FC cDNA; B, the BamHI site; and P, the PstI site. 
the amplified FC cDNA in the patient [1] with a probe 
specific for exon 4 skipping (ATT CAG AAC CCC TCA 
CA, the join sequence of exons 3 and 5). When the entire 
cDNA coding region was amplified, only one cDNA band 
of normal size was observed on the gel; the shorter band 
with exon 4 skipping could not be detected. 
Exon 4 skipping distorts the FC reading frame: a prema- 
ture stop codon renders the aberrant mRNA lacking exon 4 
very unstable. To confirm the skipping, primers were 
designed according to the exon 3 and 5 sequences to 
capture more aberrant mRNA for amplification. As ex- 
pected, an extremely faint shorter band, presumably lack- 
ing exon 4, was seen on the gel along with the normal size 
cDNA. The shorter band was then re-amplified and di- 
rectly sequenced. The exon 3 sequence was found to 
directly join the exon 5 sequence without any insertion or 
addition, thus confirming the absence of exon 4. All other 
sequences in this aberrant ranscript appeared normal. The 
mutation responsible was identified as G463 --* C, the - 1 
position of the exon 4 donor site. This is a hot spot (the 
- 1 position of an exon donor site) for splicing mutations, 
as many similar mutations have been reported in other 
genes [4-6]. The patient is heterozygous for the mutation. 
Skipping of exon 4 does not occur with 100% effi- 
ciency, as the mRNA bearing the G463 ~ C transversion 
(predicting an Ala155 ~ Pro substitution) is present at low 
levels. The FC cDNA bearing the G463 ~ C transvertion 
was thus cloned and isolated (Fig. 1). The fragment bear- 
ing the transversion was then excised and used to replace 
its normal counterpart in the FC expression vector 
pHDTF20. For a negative control, the FC cDNA lacking 
exon 7 was similarly cloned into pHDTF20 (Fig. 1, pHD- 
hoE7). Another FC missense mutation (G913 ~ T, predict- 
ing a Va1305 ~ Phe substitution), characterized by us pre- 
viously [1], was also cloned into pHDTF20 as an addi- 
tional control (pHDG913 ~ T). After transformation, the 
recombinant FC was purified according to the published 
procedure and examined by SDS-gel electrophoresis [2]. A 
single band of the recombinant FC (about 40 kDa) was 
observed for the control vector pHDTF20, in perfect agree- 
ment with the published result [2]. An identical band was 
observed for the mutation-bearing vectors pHDG463 --* C, 
pHDG913--* T and pHDnoE7, but not for JM109 host 
ceils without external transformant (Table 1). These data, 
therefore, suggested that the mutated FC was synthesized 
from pHDG463 ~ C in the expression experiments. The 
enzyme activity (U /ng  protein) was measured on cell 
homogenates and the purified recombinant FC. Compared 
to the control pHDTF20, the mutation-bearing vector 
pHDG463 ~ C showed < 3% FC activity, a level compa- 
rable to that of both the negative control pHDnoE7 and of 
JMI09 host cells without external transformant (Table 1). 
Repeated expression experiments gave consistent results. 
pHDG463--* C was also sequenced to confirm that no 
additional mutations were introduced during vector con- 
struction. These data, therefore, suggest hat the G463 ~ C 
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Table 1 
Relative FC activity of JMI09 cells transformed with various vectors 
Cells transformed Mutation 40 kDa Activity 
with vector protein (%) ~ 
band 
pHDTF20 - + 100 
pHDG463 ~ C G463 ~ C (Alal55 ~ Pro) + < 3 
PhDG913 ~ T G913 -~ T (Va1305 ~ Phe) + 120 
pHDnoE7 Exon 7 skipping + < 3 
No vector - - < 3 
Enzyme activity of pHDTF20 transformed cells, expressed in U/ng 
protein, was considered as100% 
(Alal55 ~ Pro) transversion is associated with inactivation 
of the FC activity. 
To study the inheritance pattern of the mutation, allele- 
specific oligonucleotide hybridization was performed, but 
it failed to detect he mutation in either parent. Exon 4 plus 
its flanking region was also amplified and sequenced for 
both parents, but only normal sequences were found. On 
the other hand, DNA fingerprinting indicated that both 
mother and father are the biological parents with 99.58% 
certainty [7]. These findings demonstrate that the mutation 
in the child occurred de novo. This is the first time that a 
de novo mutation has been observed in EPP. 
4. Discussions 
The mutation described in this patient has two distinct 
functional effects. 
• On the one hand, it acts as a splicing mutation causing 
exon 4 skipping. The skipping of exon 4 distorts the 
reading frame, generating a premature stop codon at 
nucleotides 713-715. This in turn gives rise to an 
inactive truncated protein of 124 amino acids. Tran- 
scripts bearing premature stop codons are often very 
unstable: this is probably the reason for the low level of 
FC mRNA lacking exon 4 observed. 
• On the other hand, when the mutant allele splices 
correctly, a mutant FC with a missense mutation 
(Ala155-Pro) that has very little catalytic activity is 
generated. The amino acid (Ala155) is conserved in 
mouse and yeast FC; thus, it appears likely that it plays 
a key role in the enzyme function. 
Consensus equences functioning in RNA splicing in- 
volve both exon and intron sequences. When mutations 
occur on the exon region, they could, depending on spe- 
cific mutations, affect both the splicing and coding of the 
protein. The same phenomenon was also observed for 
another FC mutation and other genes [1,8]. We described 
previously a G913 ~ T transversion on the + 1 position of 
the exon 9 splicing acceptor site of the FC gene [1]. The 
transversion primarily caused exon 9 skipping, but a tran- 
script bearing the G913 ~ T transversion (predicting a 
Va1305 ~ Phe substitution) was also observed. Expression 
experiment with FC cDNA bearing the G913 ~T 
transversion showed no decrease in FC activity (Table 1). 
Another such example is a G244 ~ T transversion (predic- 
ting a Va182 ~ Phe substitution) associated with congeni- 
tal erythropoietic porphyria on uroporphyrinogen III syn- 
thase gene [8]. The mutation occurred at the - 1 position 
of the exon donor splicing site and resulted in exon 
skipping in about 50% of the transcripts encoded by this 
allele. The other half of the transcripts, bearing the mis- 
sense mutation, gave rise to an enzyme with about 35% of 
normal activity. 
The exon 4 skipping was initially detected by hybridiza- 
tion of amplified FC cDNA with an oligonucleotide probe 
specific for exon 4 skipping (the exons 3 and 5 joining 
sequence that results from exon 4 skipping). The use of 
these newly created joining sequences as markers has been 
shown previously by us to be a very sensitive and efficient 
method for detecting transcripts with exon skipping [1]. 
especially those that distort the reading frame, yielding 
very unstable transcripts. 
More than a dozen EPP mutations have been identified 
[9-22]. Only a few mutations were reported in more than 
one family. Todd et al. [16] found 3 of 6 EPP families in 
Northern Ireland sharing a single base pair deletion in 
exon 1 and we found 3 EPP families sharing a splicing and 
nonsense mutation at exon 10 [14]. The majority of the 
families screened by us to date remain negative for all 
mutations currently identified. 
In the patient's family, both parents were negative for 
the mutation: this is the first de novo mutation described in 
EPP. 
Molecular defects underlying EPP appear extremely 
heterogenous, ince most reported familles have a unique 
mutation. This may reflect the fact that EPP is usually a 
mild disease and therefore very little evolutionary pressure 
is exerted on it. 
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